VICTORIA, BC, Sept. 28, 2020 /CNW/ - IMMUNOPRECISE
ANTIBODIES LTD. (the "Company" or "IPA") (TSXV: IPA) (OTCQB: IPATF)
(FSE: TQB2), a leader in full-service, therapeutic antibody
discovery and development, today announced that Dr. Jennifer
Bath, ImmunoPrecise's Chief Executive Officer, will present an
overview of the company at the Gravitas Healthcare Investor
Day on Thursday, October
1st at 11:00 AM
EST.
This year's Gravitas Healthcare Investor Day will feature
several leaders in healthcare and will be attended virtually by
institutional and retail investors from North America and abroad. For additional
details about the conference and Gravitas Securities Inc., please
visit: www.gravitassecurities.com
Conference Details:
|
Event:
|
Gravitas Healthcare
Investor Day (virtual)
|
|
Date:
|
Thursday, October
1st
|
|
Time:
|
9:00 AM – 5:30 PM
EST
|
|
Registration:
|
Link
|
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise is a
global technology platform company with end-to-end solutions
empowering companies to discover and develop therapies against any
disease. The Company's experience and cutting-edge technologies
enable unparalleled support of its partners in their quest to bring
innovative treatments to the clinic. ImmunoPrecise's full-service
capabilities dramatically reduce the time required for, and the
inherent risk associated with, conventional multi-vendor product
development. For further information, visit
www.immunoprecise.com or contact
solutions@immunoprecise.com.
SOURCE ImmunoPrecise Antibodies Ltd.